Table III.
Clinical characteristics of patients grouped by tertiles of PLR at baseline.
| Characteristic | Tertile 1 (n=213) | Tertile 2 (n=213) | Tertile 3 (n=213) | P-value |
|---|---|---|---|---|
| Age, year | 58.79±11.75 | 59.73±11.38 | 60.18±10.85 | 0.434 |
| Male, n (%) | 127 (59.62) | 135 (63.38) | 131 (61.50) | 0.728 |
| Smoking, n (%) | 95 (44.60) | 105 (49.30) | 117 (54.93) | 0.102 |
| HT, n (%) | 97 (45.54) | 91 (42.72) | 91 (42.72) | 0.795 |
| DM, n (%) | 29 (13.62) | 31 (14.55) | 39 (18.31) | 0.366 |
| History of MI, n (%) | 33 (15.49) | 38 (17.84) | 36 (16.90) | 0.808 |
| BMI, kg/m2 | 24.43±2.94 | 24.43±2.89 | 25.07±2.75 | 0.028 |
| WBC, k/ul | 7.25±1.54 | 7.27±2.06 | 7.57±2.29 | 0.191 |
| Lymphocyte, k/ul | 2.69±0.70 | 1.60±0.46 | 1.14±0.37 | <0.001 |
| PLT, k/ul | 202.28±49.10 | 222.28±51.36 | 242.50±56.13 | <0.001 |
| TC, mmol/l | 4.02±1.00 | 4.14±1.01 | 4.16±1.22 | 0.377 |
| TG, mmol/l | 1.73±0.80 | 1.68±0.69 | 1.78±0.96 | 0.517 |
| HDL-C, mmol/l | 1.03±0.21 | 1.01±0.24 | 0.99±0.24 | 0.324 |
| LDL-C, mmol/l | 2.38±0.79 | 2.44±0.97 | 2.42±0.82 | 0.806 |
| Hs-CRP, mg/l | 2.23±0.97 | 2.50±1.21 | 2.72±1.16 | <0.001 |
| Gensini score | 52.37±30.43 | 64.43±41.32 | 77.53±46.40 | <0.001 |
| Statin, n (%) | 196 (92.02) | 197 (92.49) | 194 (91.08) | 0.864 |
| ACEI/ARB, n (%) | 108 (50.70) | 105 (49.30) | 111 (52.11) | 0.957 |
| β-blocker, n (%) | 196 (92.02) | 197 (92.49) | 194 (91.08) | 0.846 |
| Aspirin, n (%) | 196 (92.02) | 195 (91.55) | 194 (91.08) | 0.941 |
Data are presented as the mean ± standard deviation. Significant differences (P<0.05) are indicated in bold. HT, hypertension; DM, diabetes mellitus; MI, myocardial infarction; BMI, body mass index; WBC, white blood cell count; PLT, platelet; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Hs-CRP, high-sensitivity c-reactive protein; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor antagonist.